Abstract
The novel gluconeogenesis inhibitor FR225654, isolated from the culture broth of Phoma sp. No. 00144, has an unique structure that consists of a highly oxygenated trans-decalin ring and a β-keto-enol, with a characteristic side chain. This compound selectively inhibited gluconeogenesis of rat primary hepatocytes and had hypoglycemic effects in several in vivo mouse models.
Similar content being viewed by others
Article PDF
References
Consoli A . Role of liver in pathophysiology of NIDDM. Diabetes Care 15: 430–441 ( 1992)
Rossetti RA, Giaccari A, Defronzo RA . Glucose toxicity. Diabetes Care 13: 610–630 ( 1990)
Ohtsu Y, Sasamura H, Tanaka M, Tsurumi Y, Yoshimura S, Takase S, Shibata T, Hino M, Nakajima H . The novel gluconeogenesis inhibitor FR225654 that originates from Phoma sp. No. 00144 I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot 58: 447–451 ( 2005)
Ohtsu Y, Yoshimura S, Kinoshita T, Takase S, Nakajima H . The novel gluconeogenesis inhibitor FR225654 that originates from Phoma sp. No. 00144 III. Structure determination. J Antibiot 58: 479–482 ( 2005)
Swanson MA . Methods Ezmymol 2: 541–543 ( 1955)
McGilvery RW . Methods Enzymol 2: 543–546 ( 1955)
Ohtsu Y, Sasamura H, Shibata T, Nakajima H, Hino M, Fujii T . The novel gluconeogenesis inhibitors FR225659 and related compounds that originate from Helicomyces sp. No.19353 II. Biological profiles. J Antibiot 56: 689–693 ( 2003)
Consoli A, Nurjhan N, Capani F, Gerich J . Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550–557 ( 1989)
Potter SC, Chandramouli V, Landou BR, Linemeyer DL, Erion MD, van Poelje PD . Effect of MB06322, a potent and selective inhibitor of fructose-1,6-bisphosphatase, on gluconeogenesis in the ZDF rat as assessed by the deuterated water technique. Diabetes 53 ( Suppl. 2): A364 ( 2004)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohtsu, Y., Sasamura, H., Shibata, T. et al. The Novel Gluconeogenesis Inhibitor FR225654 that Originates from Phoma sp. No. 00144. J Antibiot 58, 452–455 (2005). https://doi.org/10.1038/ja.2005.59
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2005.59
Keywords
This article is cited by
-
Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial
Critical Care (2012)
-
Continuous beta-lactam infusion in critically ill patients: the clinical evidence
Annals of Intensive Care (2012)
-
NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671
The Journal of Antibiotics (2010)
-
The Novel Gluconeogenesis Inhibitor FR225654 that Originates from Phoma sp. No. 00144
The Journal of Antibiotics (2005)
-
The Novel Gluconeogenesis Inhibitor FR225654 that Originates from Phoma sp. No. 00144
The Journal of Antibiotics (2005)